VitaSpring Biomedical Co. Ltd.

Performance Summary

VitaSpring Biomedical Co. Ltd. reported a net loss of $1,118,562 for fiscal year 2024, representing significant improvement from the $4,164,396 net loss in fiscal 2023. The company generated zero revenue in both periods, consistent with its development-stage status where it has not commenced commercial operations. The improvement in net loss was primarily driven by the absence of cost of goods sold, which was $3,333,000 in fiscal 2023 but zero in fiscal 2024. Operating expenses increased to $1,118,562 from $844,836, reflecting higher professional service fees and administrative costs associated with maintaining public company status. The company reported no other income in fiscal 2024 compared to $8,059 in the prior year.

Revenue Analysis

The company generated no revenue during fiscal years 2024 and 2023. VitaSpring remains in the development stage and has not commenced commercial manufacturing, distribution, or revenue-generating activities. The company's business model focuses on research-driven innovation with a long-term plan to develop, license, and commercialize proprietary technologies derived from its X.msc mesenchymal stem-cell and exosome programs. Management indicates the company is focusing on restructuring its product strategy and developing long-term partnerships rather than pursuing short-term sales. No segment revenue breakdown is available as the company operates as a single segment.

Margins & Profitability

Gross profit was zero in fiscal 2024 compared to a gross loss of $3,333,000 in fiscal 2023, representing a 100% improvement. This improvement resulted from the absence of both revenue and cost of goods sold in the current period. The company reported a loss from operations of $1,118,562 in fiscal 2024 compared to $4,177,836 in fiscal 2023. Operating expenses increased by 32.4% to $1,118,562, primarily due to higher professional-service fees and general administrative costs. The company had no income tax provision in fiscal 2024 compared to an income tax expense of $5,381 in the prior year.

Cash Flow & Balance Sheet

The company reported net cash used in operating activities of $34,920 for fiscal 2024, improved from $77,556 in fiscal 2023. Cash at January 31, 2024 was $13, compared to $29,656 at January 31, 2023. Total assets decreased to $137,342 from $765,948, while total liabilities remained elevated at $3,487,531. The company has a significant stockholders' deficit of $3,350,189 and accumulated deficit of $4,506,581. Working capital deficit stands at $3,463,904. The balance sheet shows $23,627 in total current assets against $3,487,531 in total current liabilities. Long-term assets consist primarily of equipment and vehicle ($24,063) and operating lease right-of-use asset ($89,652).

Outlook

Management has expressed substantial doubt about the company's ability to continue as a going concern within twelve months from the issuance of the financial statements. The company's minimal cash balance, recurring operating losses, and significant working capital deficit raise concerns about its ability to meet obligations. Management plans to seek additional capital through equity financing, strategic partnerships, and related-party support. The company has no committed financing arrangements and no revenue-generating operations. Key risk factors include dependence on future financing, lack of regulatory approvals, absence of issued patents, material weakness in internal controls, and significant related-party obligations totaling approximately $2.8 million. The company intends to pursue R&D programs focused on stem-cell isolation, exosome production, and formulation development once sufficient funding becomes available.